Home Tags CytomX Therapeutics

Tag: CytomX Therapeutics

Praluzatamab Ravtansine (CX-2009) Meets Primary Endpoint of ORR in HR+/HER2- Breast...

ADC Review | Editorial Team
A Phase 2 study of praluzatamab ravtansine, also known as CX-2009 (CytomX Therapeutics) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast...

Amgen and CytomX Therapeutics Agree to Jointly Develop T-Cell Engaging Bispecific...

Sonia Portillo
Amgen and CytomX Therapeutics have entered into a strategic collaboration to co-develop a Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR),...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X